JP2023552383A5 - - Google Patents

Info

Publication number
JP2023552383A5
JP2023552383A5 JP2023533889A JP2023533889A JP2023552383A5 JP 2023552383 A5 JP2023552383 A5 JP 2023552383A5 JP 2023533889 A JP2023533889 A JP 2023533889A JP 2023533889 A JP2023533889 A JP 2023533889A JP 2023552383 A5 JP2023552383 A5 JP 2023552383A5
Authority
JP
Japan
Prior art keywords
peptide
pharmaceutical composition
terminus
cancer
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552383A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/061886 external-priority patent/WO2022120226A1/en
Publication of JP2023552383A publication Critical patent/JP2023552383A/ja
Publication of JP2023552383A5 publication Critical patent/JP2023552383A5/ja
Pending legal-status Critical Current

Links

JP2023533889A 2020-12-04 2021-12-03 ペプチド受容体放射性核種療法 Pending JP2023552383A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121762P 2020-12-04 2020-12-04
US63/121,762 2020-12-04
PCT/US2021/061886 WO2022120226A1 (en) 2020-12-04 2021-12-03 Peptide receptor radionuclide therapy

Publications (2)

Publication Number Publication Date
JP2023552383A JP2023552383A (ja) 2023-12-15
JP2023552383A5 true JP2023552383A5 (cg-RX-API-DMAC7.html) 2024-12-05

Family

ID=81853616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533889A Pending JP2023552383A (ja) 2020-12-04 2021-12-03 ペプチド受容体放射性核種療法

Country Status (9)

Country Link
US (1) US12649008B2 (cg-RX-API-DMAC7.html)
EP (1) EP4255891A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023552383A (cg-RX-API-DMAC7.html)
KR (1) KR20230117581A (cg-RX-API-DMAC7.html)
CN (1) CN116829541A (cg-RX-API-DMAC7.html)
AU (1) AU2021390552A1 (cg-RX-API-DMAC7.html)
CA (1) CA3203175A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006483A (cg-RX-API-DMAC7.html)
WO (1) WO2022120226A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2025211123A1 (en) 2024-01-26 2026-08-13 The Regents Of The University Of California Peptide receptor radionuclide therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO881077L (no) * 1987-03-11 1988-09-12 Univ Michigan Kjemo-radio-immuno-konjugater.
AU2008230771B2 (en) * 2007-03-27 2014-05-08 Radiomedix Inc. Compositions for targeted imaging and therapy
WO2010047839A1 (en) * 2008-10-25 2010-04-29 Aura Biosciences Modified plant virus particles and uses therefor
WO2011082191A1 (en) * 2009-12-30 2011-07-07 Ge Healthcare Limited Method of using a 99mtc-labelled injection rgd compound and a [18f]-labelled rgd injection compound in external beam radiotherapy planning
WO2015160770A1 (en) 2014-04-15 2015-10-22 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
CN109563135B (zh) 2016-06-13 2024-01-23 加利福尼亚大学董事会 α(V)β(6)整合素结合肽及其使用方法
CN109982998A (zh) 2016-11-23 2019-07-05 癌靶技术有限责任公司 白蛋白结合psma抑制剂
GB201706472D0 (en) * 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
US11478558B2 (en) * 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
CN109091683B (zh) * 2018-08-10 2019-10-18 北京大学 一种用于整合素αvβ6靶向的环状多肽放射性药物及其制备方法
EP3846858A4 (en) 2018-09-07 2022-10-19 The Regents of the University of California ALPHA-(V)BETA(6)INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF
WO2021226432A2 (en) 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections

Similar Documents

Publication Publication Date Title
EP3766893B1 (en) 177lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen
Rosar et al. New horizons in radioligand therapy: 161Tb-PSMA-617 in advanced mCRPC
Hu et al. Efficacy and safety of stereotactic body radiotherapy combined with camrelizumab and apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus
CN111629755A (zh) 联合放射疗法治疗癌症的粒子
JP7447300B2 (ja) 放射性金属と複合するDZ-1-Lys-DOTAコンジュゲート及び使用
US6391911B1 (en) Coadministration of lucanthone and radiation for treatment of cancer
JP2023547689A5 (cg-RX-API-DMAC7.html)
EA020542B1 (ru) Альфа-излучающие частицы гидроксиапатита
WO2019094053A1 (en) Disulfiram and copper salt dosing regimen
Janssen et al. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide
Chen et al. In vivo examination of 188Re (I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer
Zulkowski et al. Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine
Sano et al. In vivo evaluation of a radiogallium-labeled bifunctional radiopharmaceutical, Ga-DOTA-MN2, for hypoxic tumor imaging
Wagman et al. Adjuvant therapy for pancreatic cancer: current treatment approaches and future challenges
Riva et al. Radioimmunotherapy of gastrointestinal cancer and glioblastomas
CN118302202A (zh) 用于治疗癌症的化合物及其组合物
Jeekel Adjuvant or neoadjuvant therapy for pancreatic carcinoma?
Yin et al. A novel CXCR4-targeted peptide for SPECT/CT imaging in tumor
KR20230117581A (ko) 펩티드 수용체 방사성 핵종 요법
CN118267494B (zh) 一种镭-224标记的金属有机框架纳米药物及其制备方法与应用
Sartor et al. Stromal targeted therapy in bone metastatic prostate cancer: promise delivered
Prieto European Association of Nuclear Medicine–35th Annual Congress. Barcelona–October 15-19, 2022
Behera et al. Ifosfamide containing regimen for non-small cell lung cancer
JP2025502955A (ja) 抗体内包金属フラーレン複合体及びその使用
Sun et al. Small cell carcinoma of the Hypopharynx